Duticin Special Precautions

Patients with hepatic impairment.
Patients with renal impairment.
Patients with infection as a complication.
Patients with chickenpox (Fetal systemic impairment may occur).
Severe side-effects such as bone marrow depression, hepatic impairment, renal impairment may occur; therefore, careful monitoring (blood-hepatic-renal function) is needed. If any symptom occurs, the administration should be discontinued or appropriate therapy instituted.
In long-term therapy, side-effects may be chronic or more severe. Therefore, careful treatment is needed.
Bleeding tendency should be cautioned.
With the effect on gonads, use in patients of child bearing age should be considered.
Others: In the long-term therapy patients, acute leukemia has been reported. Studies have demonstrated that tumor is developed when administered to animals (mice, rats) orally. Studies have been reported that spermatogenic depression is recognized. In studies using lymphocytoma of mice, mutagenicity has been recognized.
Use in children: Safe use in children has not been established.
Use in pregnancy & lactation: Studies have demonstrated that this agent is teratogenic when administered to animals. Dacarbazine therefore should not be administered to pregnant women or women who are suspected of being pregnant.
Since the safe use in nursing mothers has not been established, breast feeding should be avoided during dacarbazine therapy.